This is a pilot study to collect preliminary data to support a grant application. The goal of
the study is to evaluate whether the Food and Drug Administration (FDA)-approved and
generically-available medication buspirone reduces symptoms of opioid withdrawal among
patients undergoing a clinically-indicated and supervised taper from their opioid pain
medications. This is premised on strong preclinical scientific support but has not yet be
well-examined in humans.